Sandostatin LAR Depot

ApprovedSmall molecule

Novartis

Sandostatin LAR Depot is one of 54 small molecule programs targeting Acromegaly. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AcromegalyActive, not recruiting

ObesityActive, not recruiting

AcromegalyPhase 3

Active, not recruiting

ObesityPhase 2

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Sandostatin LAR Depot

Novartis

Approved

1 2

Actemra

Roche

Preclinical

2 3

Avapro

Sanofi

Preclinical

1 4

Adenocard

Astellas

Preclinical

—5

Colcrys

Alnylam Pharmaceuticals

Activella

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

Cetrotide

EMD Serono

Preclinical

2 9

Oxycontin

PProtega

Preclinical

1 10

Spiriva

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diarrhea1 trial

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

Completed· Novartis logo

Novartis·Phase 4·NCT00050635·150 enrolled

Acromegaly1 trial

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Terminated· Endo Pharmaceuticals logo

Endo Pharmaceuticals·Phase 3·NCT00765323·169 enrolled

ART1 trial

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Completed· Novartis logo

Novartis·Phase 4·NCT01789281·34 enrolled

Obesity1 trial

Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity

Completed· Novartis logo

Novartis·Phase 2·NCT00094146·160 enrolled

Neuroendocrine Cancer1 trial

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01121939·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Sandostatin LAR Depot. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sandostatin LAR Depot compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sandostatin LAR Depot. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Sandostatin LAR Depot

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diarrhea1 trial

Acromegaly1 trial

ART1 trial

Obesity1 trial

Neuroendocrine Cancer1 trial

References

Drug Info

Quick Facts

Related News